Abstract
Purpose :
To investigate prospectively long-term functional and anatomical outcomes for fixed regimen of intravitreal aflibercept in patients with CNV by quantitative analysis based on OCT and swept-source OCT angiography.
Methods :
33 patients who are diagnosed as CNV are enrolled for prospective, signle arm, interventional study. At first, 3 intravitreal aflibercept injections by monthly and 5 intravitreal aflibercept injections by fixed every 2 months regimen were done. Investigation of functional and anatomical outcomes were performed every 1 week later after intravitreal aflibercept injection. Analysis of 33 eyes with follow-up for 49 weeks were done for BCVA(ETDRS), CST, PED volume, CNV area, vessel density and vessel length density prospectively.
Results :
Average baseline of age was 72.38±8.82 and BCVA(ETDRS) was 50.27±23.57. There were significant correlation between last vessel length density and last BCVA(r=-0.765, p=0.006), last CNV area and last CST(r=-0.743, p=0.009), toal change of vessel density and last CST(r=-0.651, p=0.030), total change of vessel density and first change of CST(r = 0.709, p =0.022). As a result of multiple regression analysis, the dependent variable, last CST, was statistically significant with a variable as total change of CNV vessel density in the independent variable.
Conclusions :
Fixed 2-months regimen of aflibercept improved both visual and anatomical outcomes in patients with neovascular AMD at 49 weeks. Also OCTA biomarkers can be used for evaluating neovascular AMD.
This is a 2021 ARVO Annual Meeting abstract.